Literature DB >> 17520224

Treatment for autoimmune pancreatitis: consensus on the treatment for patients with autoimmune pancreatitis in Japan.

Tetsuhide Ito1, Isao Nishimori, Naoko Inoue, Ken Kawabe, Junya Gibo, Yoshiyuki Arita, Kazuichi Okazaki, Ryoichi Takayanagi, Makoto Otsuki.   

Abstract

Autoimmune pancreatitis (AIP) has been characterized by unique clinical imaging, immunological findings, and the effectiveness of steroid therapy. A set of clinicopathological criteria for AIP was proposed by the Japan Pancreatic Society in 2002, and AIP has come to be widely recognized among general digestive clinicians. However, the indication of steroid therapy for AIP is still not well established, and furthermore the therapeutic doses and method of administration of steroid therapy is also unclear. Recently, an epidemiological survey of all the treatments used for AIP in Japan was conducted by the Research Committee of Intractable Pancreatic Diseases, and their report "Consensus for a Treatment of Autoimmune Pancreatitis" was produced. In a comparison of the results of steroid therapy and nonsteroid therapy for AIP in relation to the rate of complete remission, the recurrence rate, and the period needed to guarantee complete remission, it was thought that the administration of a steroid should be a standard therapy for AIP. However, if the diagnosis of AIP is still uncertain, steroid therapy should be given with caution. In addition, even when AIP still appears to be possible after a course of steroid therapy, a re-evaluation should be carried out taking pancreatic carcinoma into consideration. An initial steroid dose of 30-40 mg per day is recommended. With continuous and careful observations of the clinical manifestations, laboratory data, and imaging findings after administration of the initial dose of steroid for 2-4 weeks, the quantity of steroid can be reduced gradually to a maintenance dose in 2-3 months, and then reduced to 2.5-5 mg per day after remission. The recommended period of maintenance treatment is still unclear, but the administration of the steroid could be stopped after a period of about 6-12 months of treatment, although the patient should be monitored for clinical manifestations of improvement. In addition, the patient's progress should be followed taking recurrence into consideration. In order to evaluate the effectiveness of steroid therapy, follow-up observations should include biochemical examinations of blood findings such as serum gamma-globulin, IgG, and IgG 4, imaging findings, and clinical manifestations such as jaundice and abdominal discomfort.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17520224     DOI: 10.1007/s00535-007-2051-y

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  25 in total

Review 1.  Primary sclerosing cholangitis: updates in diagnosis and therapy.

Authors:  Piero Portincasa; Michele Vacca; Antonio Moschetta; Michele Petruzzelli; Giuseppe Palasciano; Karel J van Erpecum; Gerard P van Berge-Henegouwen
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

2.  Influence of steroid therapy on the course of diabetes mellitus in patients with autoimmune pancreatitis: findings from a nationwide survey in Japan.

Authors:  Isao Nishimori; Akiko Tamakoshi; Shigeyuki Kawa; Shigeki Tanaka; Kazuo Takeuchi; Terumi Kamisawa; Hiromitsu Saisho; Kenji Hirano; Keiya Okamura; Nobuyuki Yanagawa; Makoto Otsuki
Journal:  Pancreas       Date:  2006-04       Impact factor: 3.327

3.  High serum IgG4 concentrations in patients with sclerosing pancreatitis.

Authors:  H Hamano; S Kawa; A Horiuchi; H Unno; N Furuya; T Akamatsu; M Fukushima; T Nikaido; K Nakayama; N Usuda; K Kiyosawa
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

4.  Autoimmune pancreatitis: etiology, pathogenesis, clinical findings and treatment. The Japanese experience.

Authors:  Kazuichi Okazaki
Journal:  JOP       Date:  2005-01-13

Review 5.  Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis.

Authors:  K Yoshida; F Toki; T Takeuchi; S Watanabe; K Shiratori; N Hayashi
Journal:  Dig Dis Sci       Date:  1995-07       Impact factor: 3.199

6.  Cholangiography can discriminate sclerosing cholangitis with autoimmune pancreatitis from primary sclerosing cholangitis.

Authors:  Takahiro Nakazawa; Hirotaka Ohara; Hitoshi Sano; Shigeru Aoki; Shinya Kobayashi; Tetsu Okamoto; Hideto Imai; Tomoyuki Nomura; Takashi Joh; Makoto Itoh
Journal:  Gastrointest Endosc       Date:  2004-12       Impact factor: 9.427

7.  Long-term outcome of autoimmune pancreatitis after oral prednisolone therapy.

Authors:  Takayoshi Nishino; Fumitake Toki; Hiroyasu Oyama; Kyoko Shimizu; Keiko Shiratori
Journal:  Intern Med       Date:  2006-05-15       Impact factor: 1.271

8.  Corticosteroid-responsive diabetes mellitus associated with autoimmune pancreatitis.

Authors:  S Tanaka; T Kobayashi; K Nakanishi; M Okubo; T Murase; M Hashimoto; K Takeuchi
Journal:  Lancet       Date:  2000-09-09       Impact factor: 79.321

Review 9.  Autoimmune pancreatitis: pathological, clinical, and immunological features.

Authors:  Günter Klöppel; Jutta Lüttges; Matthias Löhr; Giuseppe Zamboni; Daniel Longnecker
Journal:  Pancreas       Date:  2003-07       Impact factor: 3.327

10.  Autoimmune pancreatitis successfully treated with ursodeoxycholic acid.

Authors:  Kazumi Tsubakio; Kazuo Kiriyama; Nobuyoshi Matsushima; Masahiro Taniguchi; Takae Shizusawa; Tetsuya Katoh; Noriko Manabe; Michihiro Yabu; Yoshio Kanayama; Seiichi Himeno
Journal:  Intern Med       Date:  2002-12       Impact factor: 1.271

View more
  36 in total

1.  Autoimmune Pancreatitis and IgG4-Related Disease: The Storiform Discovery to Treatment.

Authors:  Kazuichi Okazaki
Journal:  Dig Dis Sci       Date:  2019-09       Impact factor: 3.199

Review 2.  Japanese consensus guidelines for management of autoimmune pancreatitis: I. Concept and diagnosis of autoimmune pancreatitis.

Authors:  Kazuichi Okazaki; Shigeyuki Kawa; Terumi Kamisawa; Toru Shimosegawa; Masao Tanaka
Journal:  J Gastroenterol       Date:  2010-03       Impact factor: 7.527

3.  Factors predictive of relapse and spontaneous remission of autoimmune pancreatitis patients treated/not treated with corticosteroids.

Authors:  Kensuke Kubota; Seitaro Watanabe; Takashi Uchiyama; Shingo Kato; Yusuke Sekino; Kaori Suzuki; Hironori Mawatari; Hiroshi Iida; Hiroki Endo; Koji Fujita; Masato Yoneda; Hirokazu Takahashi; Hiroyuki Kirikoshi; Noritoshi Kobayashi; Satoru Saito; Kazuya Sugimori; Kantaro Hisatomi; Nobuyuki Matsuhashi; Hirotaka Sato; Emiko Tanida; Takashi Sakaguchi; Nobutaka Fujisawa; Atsushi Nakajima
Journal:  J Gastroenterol       Date:  2011-04-15       Impact factor: 7.527

4.  Hepatopancreatobiliary manifestations of inflammatory bowel disease.

Authors:  Kazuhiko Nakamura; Tetsuhide Ito; Kazuhiro Kotoh; Eikichi Ihara; Haruei Ogino; Tsutomu Iwasa; Yoshimasa Tanaka; Yoichiro Iboshi; Ryoichi Takayanagi
Journal:  Clin J Gastroenterol       Date:  2012-01-06

5.  Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 I. Concept and diagnosis of autoimmune pancreatitis.

Authors:  Kazuichi Okazaki; Shigeyuki Kawa; Terumi Kamisawa; Tetsuhide Ito; Kazuo Inui; Hiroyuki Irie; Takayoshi Nishino; Kenji Notohara; Isao Nishimori; Shigeki Tanaka; Toshimasa Nishiyama; Koichi Suda; Keiko Shiratori; Masao Tanaka; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2014-03-18       Impact factor: 7.527

6.  Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis.

Authors:  Terumi Kamisawa; Kazuichi Okazaki; Shigeyuki Kawa; Tetsuhide Ito; Kazuo Inui; Hiroyuki Irie; Takayoshi Nishino; Kenji Notohara; Isao Nishimori; Shigeki Tanaka; Toshimasa Nishiyama; Koichi Suda; Keiko Shiratori; Masao Tanaka; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2014-03-18       Impact factor: 7.527

7.  Treatment and relapse of autoimmune pancreatitis.

Authors:  Sung-Hoon Moon; Myung-Hwan Kim; Do Hyun Park
Journal:  Gut Liver       Date:  2008-06-30       Impact factor: 4.519

8.  Impact of hyperglycemia on autoimmune pancreatitis and regulatory T-cells.

Authors:  Franz-Tassilo Müller-Graff; Brit Fitzner; Robert Jaster; Brigitte Vollmar; Dietmar Zechner
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

9.  Insulin secretion improvement during steroid therapy for autoimmune pancreatitis according to the onset of diabetes mellitus.

Authors:  Kensaku Noguchi; Yousuke Nakai; Suguru Mizuno; Hiroyuki Isayama; Kenji Hirano; Sachiko Kanai; Tomoka Nakamura; Rie Uchino; Naminatsu Takahara; Hirofumi Kogure; Minoru Tada; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2019-08-30       Impact factor: 7.527

Review 10.  Retroperitoneal fibrosis associated with immunoglobulin G4-related disease.

Authors:  Nao Fujimori; Tetsuhide Ito; Hisato Igarashi; Takamasa Oono; Taichi Nakamura; Yusuke Niina; Masayuki Hijioka; Lingaku Lee; Masahiko Uchida; Ryoichi Takayanagi
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.